NCI maintains paylines for early-stage investigators, cuts funding for other R01s and noncompeting grants in FY24

NCI renews MUSC Hollings support grant with “outstanding” rating

NCI has renewed MUSC Hollings Cancer Center’s five-year Cancer Center Support Grant, with an overall rating of “outstanding.”

April 19, 2024

Vol.50 No.16

Clinical

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.

April 12, 2024

Vol.50 No.15

By Jacquelyn Cobb

NCI Director's Report

Rathmell: To improve funding outlook, we must reverse distrust in science

With NCI funding expected to remain flat through fiscal year 2025, health professionals and leaders in oncology should use this time to amp up institutional efforts to collaborate and rebuild trust in science, NCI Director Kimryn Rathmell said.

April 12, 2024

Vol.50 No.15

By Matthew Bin Han Ong

Health Equity

NCI creates Cancer Equity Leaders group to improve cancer health equity

To address inequities in cancer health, NCI is collaborating with a diverse team of experts and cancer center directors—named the Cancer Equity Leaders (CEL)—to learn from communities and inform workforce development as well as outreach initiatives.

April 12, 2024

Vol.50 No.15

By Matthew Bin Han Ong

Funding Opportunities

DOD Lung Cancer Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act provides funding for the LCRP to support innovative, high-impact lung cancer research. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.

April 12, 2024

Vol.50 No.15